Quoin Pharmaceuticals Receives Patent Allowance for Netherton Syndrome Treatment

Quoin Pharmaceuticals announced that the USPTO has issued a Notice of Allowance for a patent application titled "Combination Treatment for Netherton Syndrome." This patent supports the intellectual property strategy for QRX003, its investigational treatment for Netherton Syndrome, a rare genetic skin disease with no approved treatments. The allowed claims cover a method of treating the condition using a topical serine protease inhibitor and an anti-inflammatory agent, including patients with SPINK5 mutations. This development strengthens the long-term value of the QRX003 program, which has multiple regulatory designations and is progressing towards a potential NDA filing in 2027.